Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 15/20 | 0.41 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.32 |
| ▸ | CPT2 | P23786 | 2/20 | 0.32 |
| ▸ | CPT1A | P50416 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4902404 | 0.92 | CNR1 (0.47) | CNR1MCOLN3 | |
| SCHEMBL4923174 | 0.91 | CNR1 (0.42) | CNR1CXCR3 | |
| SCHEMBL4915199 | 0.84 | CNR1 (0.58) | CNR1 | |
| SCHEMBL4913958 | 0.83 | CNR1 (0.51) | CNR1 | |
| SCHEMBL4922305 | 0.82 | CNR1 (0.36) | CNR1CXCR3 | |
| SCHEMBL4917463 | 0.81 | CNR1 (0.61) | CNR1 | |
| SCHEMBL4796011 | 0.79 | CNR1 (0.36) | CNR1MCOLN3 | |
| SCHEMBL4922312 | 0.78 | CNR1 (0.41) | CNR1 | |
| SCHEMBL4637589 | 0.77 | CNR1 (0.69) | CNR1 | |
| SCHEMBL4925530 | 0.76 | CNR1 (0.51) | CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080319019-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | claimed |
| US-20080319019-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319019-A1 | Therapeutic Agents | SDHA, GPR119, ABAT | CNR1 393/4885CXCR3 4701/4885MCHR1 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.